$VVOS
Vivos Therapeutics, Inc. Stock $vvos

$vvos Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223020568 Filed on June 08, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$3.395M	$3.857M	$3.460M
YoY Change	-18.86%	11.47%	0.29%
Cost Of Revenue	$100.0K	$100.0K	$1.093M
YoY Change	0.0%	-90.85%	43.82%
Gross Profit	$2.098M	$2.337M	$2.367M
YoY Change	-18.93%	-1.27%	-12.01%
Gross Profit Margin	61.8%	60.59%	68.41%
Selling, General & Admin	$6.467M	$7.167M	$9.028M
YoY Change	-31.13%	-20.61%	52.5%
% of Gross Profit	308.25%	306.68%	381.41%
Research & Development	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%
% of Gross Profit	4.77%	4.28%	4.22%
Depreciation & Amortization	$148.0K	$175.0K	$41.00K
YoY Change	-26.0%	326.83%	-77.22%
% of Gross Profit	7.05%	7.49%	1.73%
Operating Expenses	$6.615M	$7.342M	$9.190M
YoY Change	-30.75%	-20.11%	50.9%
Operating Profit	-$4.517M	-$5.005M	-$6.823M
YoY Change	-35.14%	-26.65%	100.68%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$225.0K	$51.00K	$21.00K
YoY Change	703.57%	142.86%
Pretax Income	-$5.528M	-$1.703M	-$5.515M
YoY Change	-20.94%	-69.12%	62.21%
Income Tax
% Of Pretax Income
Net Earnings	-$5.528M	-$1.703M	-$5.515M
YoY Change	-20.94%	-69.12%	62.21%
Net Earnings / Revenue	-162.83%	-44.15%	-159.39%
Basic Earnings Per Share	-$0.18	-$0.07	-$0.25
Diluted Earnings Per Share	-$0.18	-$0.07	-$259.7K
COMMON SHARES
Basic Shares Outstanding	29.93M shares	29.68M shares	21.23M shares
Diluted Shares Outstanding	29.93M shares	990.7K shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.942M	$7.046M	$17.83M
YoY Change	-68.87%	-60.48%	26.8%
Cash & Equivalents	$3.900M	$7.000M	$17.83M
Short-Term Investments
Other Short-Term Assets	$1.073M	$1.346M	$2.771M
YoY Change	-47.94%	-51.43%	197.96%
Inventory
Prepaid Expenses
Receivables	$327.0K	$321.0K	$1.002M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.342M	$8.713M	$21.60M
YoY Change	-65.56%	-59.66%	29.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.267M	$3.157M	$4.427M
YoY Change	5.08%	-28.69%	317.64%
Goodwill	$2.843M	$2.843M
YoY Change	0.0%
Intangibles	$445.0K	$458.0K
YoY Change	38.2%
Long-Term Investments
YoY Change
Other Assets	$308.0K	$308.0K	$354.0K
YoY Change	-17.43%	-12.99%	-4.32%
Total Long-Term Assets	$8.407M	$8.387M	$7.955M
YoY Change	-5.13%	5.43%	52.69%
TOTAL ASSETS
Total Short-Term Assets	$5.342M	$8.713M	$21.60M
Total Long-Term Assets	$8.407M	$8.387M	$7.955M
Total Assets	$13.75M	$17.10M	$29.56M
YoY Change	-43.59%	-42.14%	34.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.325M	$1.495M	$877.0K
YoY Change	5.83%	70.47%	0.8%
Accrued Expenses	$1.949M	$1.940M	$3.529M
YoY Change	-25.55%	-45.03%	43.46%
Deferred Revenue	$2.359M	$2.647M
YoY Change	13.41%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.440M	$7.975M	$6.851M
YoY Change	26.08%	16.41%	-6.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$3.203M	$2.132M	$1.850M
YoY Change	12.7%	15.24%	780.95%
Total Long-Term Liabilities	$3.203M	$2.132M	$1.850M
YoY Change	12.7%	15.24%	478.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.440M	$7.975M	$6.851M
Total Long-Term Liabilities	$3.203M	$2.132M	$1.850M
Total Liabilities	$11.60M	$10.10M	$8.701M
YoY Change	22.11%	16.08%	14.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$86.70M	-$81.20M
YoY Change	27.69%
Common Stock	$3.000K	$3.000K
YoY Change	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.106M	$6.993M	$20.86M
YoY Change
Total Liabilities & Shareholders Equity	$13.75M	$17.10M	$29.56M
YoY Change	-43.59%	-42.14%	34.65%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$5.528M	-$1.703M	-$5.515M
YoY Change	-20.94%	-69.12%	62.21%
Depreciation, Depletion And Amortization	$148.0K	$175.0K	$41.00K
YoY Change	-26.0%	326.83%	-77.22%
Cash From Operating Activities	-$2.859M	-$3.500M	-$6.082M
YoY Change	-38.69%	-42.45%	57.56%
INVESTING ACTIVITIES
Capital Expenditures	$245.0K	$239.0K	-$120.0K
YoY Change	-148.61%	-299.17%	-53.85%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$50.00K
YoY Change
Cash From Investing Activities	-$245.0K	-$289.0K	-$120.0K
YoY Change	-51.39%	140.83%	-53.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$7.355M
YoY Change
NET CHANGE
Cash From Operating Activities	-2.859M	-$3.500M	-6.082M
Cash From Investing Activities	-245.0K	-$289.0K	-120.0K
Cash From Financing Activities	0.000	$7.355M
Net Change In Cash	-3.104M	$3.527M	$0.00
YoY Change	-39.93%		-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.859M	-$3.500M	-$6.082M
Capital Expenditures	$245.0K	$239.0K	-$120.0K
Free Cash Flow	-$3.104M	-$3.739M	-$5.962M
YoY Change	-25.37%	-37.29%	65.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001716166
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	VVOS	Gain Loss On Ppp Loan Forgiveness GainLossOnPPPLoanForgiveness		usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets		usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2022Q1	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue		usd
CY2023Q1	VVOS	Forgiveness Of Indebtness Income ForgivenessOfIndebtnessIncome		usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
CY2022Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	VVOS	Fair Value Of Prefunded Warrants Exercised FairValueOfPrefundedWarrantsExercised		usd
CY2022Q1	VVOS	Fair Value Of Common Stock Issued In Asset Purchase FairValueOfCommonStockIssuedInAssetPurchase		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39796
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Vivos Therapeutics, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3224056
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7921 Southpark Plaza
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Littleton
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80120
CY2023Q1	dei	City Area Code CityAreaCode	(866)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	908-4867
CY2023Q1	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	VVOS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29928786	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7046000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3519000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	672000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	712000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	321000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	457000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1346000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1448000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	8713000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5424000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	2843000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2843000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3157000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3082000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1621000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1695000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	458000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	302000	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	308000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	374000	usd
CY2023Q1	us-gaap	Assets Assets	17100000	usd
CY2022Q4	us-gaap	Assets Assets	13720000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1495000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1411000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1940000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1912000	usd
CY2023Q1	VVOS	Warrant Liability WarrantLiability	1333000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2647000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2926000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	433000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	419000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	127000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	145000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7975000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6813000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	250000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	112000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1882000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1994000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	10107000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8919000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29928786	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29928786	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23012119	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23012119	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88161000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	84267000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81171000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-79468000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6993000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4801000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17100000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13720000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3857000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3644000	usd
CY2023Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1520000	usd
CY2022Q1	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1093000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	2337000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	2551000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6537000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8275000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	630000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	753000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	175000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	162000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	7342000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	9190000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5005000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6639000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	51000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000	usd
CY2022Q1	VVOS	Gain Loss On Ppp Loan Forgiveness GainLossOnPPPLoanForgiveness	-1287000	usd
CY2023Q1	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue	6453000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	645000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9628000	usd
CY2023Q1	VVOS	Other Income Non Operating OtherIncomeNonOperating	76000	usd
CY2022Q1	VVOS	Other Income Non Operating OtherIncomeNonOperating	59000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1703000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5331000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24764041	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	25539000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	222000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	609000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5331000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	21039000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	21039000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4801000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4801000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	116000	usd
CY2023Q1	VVOS	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	2848000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	625000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	306000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1703000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6993000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6993000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1703000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5331000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	306000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	609000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	175000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	41000	usd
CY2023Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	625000	usd
CY2022Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	222000	usd
CY2023Q1	us-gaap	Payments Of Derivative Issuance Costs PaymentsOfDerivativeIssuanceCosts	645000	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	9628000	usd
CY2023Q1	VVOS	Excess Warrant Fair Value ExcessWarrantFairValue	6453000	usd
CY2022Q1	VVOS	Forgiveness Of Indebtness Income ForgivenessOfIndebtnessIncome	1265000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-136000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-201000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-25000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-19000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-102000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	680000	usd
CY2023Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-79000	usd
CY2022Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-3000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	84000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-42000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	28000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	419000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-31000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-140000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-240000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3539000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6082000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	239000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	120000	usd
CY2023Q1	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	50000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-289000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-120000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	8000000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	645000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7355000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3527000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6202000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3519000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24030000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7046000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17828000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2023Q1	VVOS	Fair Value Of Prefunded Warrants Exercised FairValueOfPrefundedWarrantsExercised	1000	usd
CY2023Q1	VVOS	Fair Value Of Common Stock Issued In Asset Purchase FairValueOfCommonStockIssuedInAssetPurchase	116000	usd
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zCQ0RQJelwM5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86C_zBZWCJnWrsul">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires the Company to make judgments, assumptions, and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. The Company bases its estimates and assumptions on existing facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company’s significant accounting estimates include, but are not necessarily limited to, assessing collectability on accounts receivable, the determination of customer life and breakage related to recognizing revenue for VIP contracts, notes receivable, impairment of goodwill and long-lived assets; valuation assumptions for assets acquired in asset acquisitions; valuation assumptions for stock options, warrants, warrant liabilities and equity instruments issued for goods or services; deferred income taxes and the related valuation allowances; and the evaluation and measurement of contingencies. Additionally, the full impact of COVID-19 is unknown and cannot be reasonably estimated. However, the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.10
CY2023Q1	VVOS	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P4Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1758000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.42
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3619000	shares
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.89
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y3M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	500000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3119000	shares
CY2023Q1	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.
CY2023Q1	VVOS	Warrant Accounting Policy Textblock WarrantAccountingPolicyTextblock	<p id="xdx_845_ecustom--WarrantAccountingPolicyTextblock_zG78wQB649wa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zVA4hupznI23">Warrant Accounting</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its warrants and financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with <i>ASC 815, Derivatives and Hedging</i>. Warrants classified as equity are recorded at fair value as of the date of issuance on the Company’s consolidated balance sheets and no further adjustments to their valuation are made. Warrants classified as liabilities and other financial instruments that require separate accounting as liabilities are recorded on the Company’s consolidated balance sheets at their fair value on the date of issuance and will be revalued on each subsequent balance sheet date until such instruments are exercised or expire, with any changes in the fair value between reporting periods recorded as other income or expense. Management estimates the fair value of these liabilities using the Black-Scholes model and assumptions that are based on the individual characteristics of the warrants or instruments on the valuation date, as well as assumptions for future financings, expected volatility, expected life, yield, and risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i/></b></span></p>
CY2023Q1	us-gaap	Profit Loss ProfitLoss	1700000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	5300000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81200000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3500000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6100000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	10100000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7000000.0	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3857000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3644000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3038000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2399000	usd
CY2023Q1	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1255000	usd
CY2022Q1	VVOS	Contract With Customer Liability During The Period ContractWithCustomerLiabilityDuringThePeriod	1183000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1396000	usd
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-1421000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2897000	usd
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2161000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2600000	usd
CY2023Q1	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	200000	usd
CY2022Q1	VVOS	Revenue From Breakage On Contract Liabilities RevenueFromBreakageOnContractLiabilities	400000	usd
CY2023Q1	us-gaap	Receivables From Customers ReceivablesFromCustomers	500000	usd
CY2023Q1	us-gaap	Receivables From Customers ReceivablesFromCustomers	300000	usd
CY2023Q1	VVOS	Provision For General And Administrative Expense ProvisionForGeneralAndAdministrativeExpense	700000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5074000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4835000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1917000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1753000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3157000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3082000	usd
CY2023Q1	us-gaap	Area Of Land AreaOfLand	15000	sqft
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	2800000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2800000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	2843000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2843000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2659000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2493000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2201000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2191000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	458000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	302000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	37000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	50000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	50000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	35000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	30000	usd
CY2023Q1	VVOS	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	256000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	458000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1303000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1358000	usd
CY2023Q1	VVOS	Accrued Legal And Other AccruedLegalAndOther	592000	usd
CY2022Q4	VVOS	Accrued Legal And Other AccruedLegalAndOther	473000	usd
CY2023Q1	VVOS	Accrued Lab Rebate Liabilities Current AccruedLabRebateLiabilitiesCurrent	45000	usd
CY2022Q4	VVOS	Accrued Lab Rebate Liabilities Current AccruedLabRebateLiabilitiesCurrent	81000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1940000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1912000	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	250000	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	50000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	200000	usd
CY2023Q1	us-gaap	Cash Cash	200000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	400000	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.61
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	500000	usd
CY2023Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2023Q1	VVOS	Vested Warrants VestedWarrants	0	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	130000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	127000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	130000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	127000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083	pure
CY2023Q1	VVOS	Schedule Of Cash Flow Information Related To Leases ScheduleOfCashFlowInformationRelatedToLeases	<p id="xdx_891_ecustom--ScheduleOfCashFlowInformationRelatedToLeases_zjryCImYBipj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to leases as of March 31, 2023 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zOiytHEwtdA2" style="display: none">SCHEDULE OF RELATED TO LEASES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_491_20230101__20230331_zKaQxVeQFsKc" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cash flow classification of lease payments:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--OperatingCashFlowsFromOperatingLeases_pn3n3_z04kyIRBGpeh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 80%; text-align: left">Operating cash flows from operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">148</td><td style="width: 1%; text-align: left"> </td></tr> </table>
CY2023Q1	VVOS	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	148000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	454000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	621000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	594000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	507000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	493000	usd
CY2023Q1	VVOS	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	140000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2809000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	494000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2315000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1703000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5331000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1703000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5331000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24764041	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21233485	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15491	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7235	shares
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	14453000	usd
CY2023Q1	VVOS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Exercise FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityExercise	2847000	usd
CY2023Q1	VVOS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Change In Fair Value Upon Remeasurement FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInFairValueUponRemeasurement	10273000	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1333000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7000000.0	usd

Files In Submission

Name	View Source	Status
0001493152-23-020568-index-headers.html	Edgar Link	pending
0001493152-23-020568-index.html	Edgar Link	pending
0001493152-23-020568.txt	Edgar Link	pending
0001493152-23-020568-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vvos-20230331.xsd	Edgar Link	pending
vvos-20230331_cal.xml	Edgar Link	unprocessable
vvos-20230331_lab.xml	Edgar Link	unprocessable
vvos-20230331_def.xml	Edgar Link	unprocessable
vvos-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VVOS
Vivos Therapeutics, Inc. Stock $vvos

2023 Q2 Form 10-Q Financial Statement

#000149315223020568 Filed on June 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VVOS Vivos Therapeutics, Inc. Stock $vvos

2023 Q2 Form 10-Q Financial Statement

#000149315223020568 Filed on June 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VVOS
Vivos Therapeutics, Inc. Stock $vvos